GlassScriptPhysician profile
Sharon Tan
NPI 1801810668
$7,304.40
in general payments reported to CMS, 2019-2025
37 companies · $823 in 2025
The $823 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $678 · 2021: $1,449 · 2022: $1,070 · 2023: $1,409 · 2024: $1,168 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.29 |
| Education | $129.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,166.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $855.68 | 2021-2025 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $713.48 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $518.30 | 2019-2025 | |
| Glaxosmithkline, LLC. | $478.88 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $376.09 | 2019-2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $334.78 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.30 | 2019-2024 | Jardiance |
| Abbott Laboratories | $301.55 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $249.32 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.05 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $194.83 | 2019-2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $167.88 | 2019-2024 | Trintellix |
| Actelion Pharmaceuticals US, INC. | $130.16 | 2024-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $126.84 | 2020-2025 | Breztri, Farxiga |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.